Rheumatol Ther. 2022. Epub ahead of print doi: 10.1007/s40744-022-00511-3
This post hoc analysis of data from the ORAL Shift study, concludes that DAS28-4(ESR), CDAI remission and SDAI remission are the metrics most likely to reflect actual disease activity, in the context of tofacitinib in a randomised withdrawal of MTX.
With a number of patients with RA discontinuing MTX due to intolerance and/or preference, an understanding of the effectiveness of tofacitinib monotherapy in maintaining disease control following MTX withdrawal is of clinical relevance. As such, Fleischmann, et al. evaluated the performance of various disease activity metrics, including SDAI, DAS28-4(CRP) and RAPID3, to understand how treatment response rates can vary depending on the system of measurement used. A consistent trend towards higher response rates with Tofacitinib plus MTX compared with Tofacitinib monotherapy was reported.